BIO, Allergan and Roche Call for FDA Flexibility With Patient Experience Data

Industry group BIO and biopharma companies Allergan and Roche are calling for the US Food and Drug Administration (FDA) to be flexible in its approach for using patient experience data (PED) and in allowing the use of such data in labeling.